HDAC9 and cancer: Pharmacological studies of suberanilohydroxamic acid (SAHA, Vorinostat), a broad inhibitor of class I and II HDAC enzymes (Bubna, 2015), in different types of cancers indicate that SAHA is well tolerated and demonstrates good oral bioavailability (43%) (Kelly et al., 2005).